［1］Ferlay J，Soerjomataram I，Dikshit R，et al.Cancer incidence and mortality worldwide：Sources，methods and major patterns in globocan 2012 ［J］.International Journal of Cancer，2015,136(5):E359-386.
［2］Cronin KA，Lake AJ，Scott S，et al.Annual report to the nation on the status of cancer，part Ⅰ：National cancer statistics ［J］.Cancer，2018,124(13):2785-2800.
［3］HU QY，YU ZJ.Advances in molecular targeted therapies for primary hepatocellular carcinoma［J］.International Journal of Digestive Diseases,2017,37(01):20-23.［胡秋月,余祖江.分子靶向治疗药物在原发性肝癌中的研究进展［J］.国际消化病杂志,2017,37(01):20-23.］
［4］Qin S，Bai Y，Lim HY，et al.Randomized，multicenter，open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from asia ［J］.J Clinical Oncology，2013,31(28):3501-3508.
［5］Tanaka S，Arii S.Molecularly targeted therapy for hepatocellular carcinoma ［J］.Cancer Science，2009,100(1):1-8.
［6］Rimassa L，Santoro A.Sorafenib therapy in advanced hepatocellular carcinoma：The sharp trial ［J］.Expert Review of Anticancer Therapy，2009,9(6):739-745.
［7］Cheng AL，Kang YK，Chen Z，et al.Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma:A phase Ⅲ randomised，double-blind，placebo-controlled trial ［J］.The Lancet Oncology，2009,10(1):25-34.
［8］Bruix J，Cheng AL，Meinhardt G，et al.Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma：Analysis of two phase Ⅲ studies ［J］.Journal of Hepatology，2017,67(5):999-1008.
［9］Ganten TM，Stauber RE，Schott E，et al.Sorafenib in patients with hepatocellular carcinoma-results of the observational insight study ［J］.Clinical Cancer Research,2017,23(19):5720-5728.
［10］Yamamoto Y，Matsui J，Matsushima T，et al.Lenvatinib，an angiogenesis inhibitor targeting VEGFR/FGFR,shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage ［J］.Vascular cell，2014,6(1).doi:10.1186/2045-824X-6-18.
［11］Ikeda K，Kudo M，Kawazoe S，et al.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma ［J］.Journal of Gastroenterology，2017,52(4):512-519.
［12］Kudo M，Finn RS，Qin S，et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma：A randomised phase 3 non-inferiority trial ［J］.The Lancet，2018,391(10126):1163-1173.
［13］Abou-Elkacem L，Arns S，Brix G，et al.Regorafenib inhibits growth，angiogenesis，and metastasis in a highly aggressive，orthotopic colon cancer model ［J］.Molecular Cancer Therapeutics，2013,12(7):1322-1331.
［14］Bruix J，Qin S，Merle P，et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment（resorce)：A randomised，double-blind，placebo-controlled，phase 3 trial ［J］.The Lancet，2017,389(10064):56-66.
［15］Spratlin JL，Cohen RB，Eadens M，et al.Phase Ⅰ pharmacologic and biologic study of ramucirumab（IMC-1121b)，a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 ［J］.J Clinical Oncology，2010,28(5):780-787.
［16］Zhu AX，Park JO，Ryoo BY，et al.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib（reach)：A randomised，double-blind，multicentre，phase 3 trial ［J］.The Lancet Oncology，2015,16(7):859-870.
［17］Xiang Q，Chen W，Ren M，et al.Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and met ［J］.Clinical Cancer Research,2014,20(11):2959-2970.
［18］Llovet JM，Montal R，Sia D，et al.Molecular therapies and precision medicine for hepatocellular carcinoma ［J］.Nature reviews Clinical Oncology，2018,15(10):599-616.
［19］Kelley RK，Verslype C，Cohn AL，et al.Cabozantinib in hepatocellular carcinoma：Results of a phase 2 placebo-controlled randomized discontinuation study ［J］.Annals of Oncology，2017,28(3):528-534.
［20］Abou-Alfa GK，Meyer T，Cheng AL，et al.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma ［J］.The New England Journal of Medicine，2018,379(1):54-63.
［21］Whiteside TL，Demaria S，Rodriguez-Ruiz ME，et al.Emerging opportunities and challenges in cancer immunotherapy ［J］.Clinical Cancer Research，2016,22(8):1845-1855.
［22］Prieto J，Melero I，Sangro B.Immunological landscape and immunotherapy of hepatocellular carcinoma ［J］.Nature Reviews Gastroenterology & Hepatology，2015,12(12):681-700.
［23］El-Khoueiry AB，Sangro B，Yau T，et al.Nivolumab in patients with advanced hepatocellular carcinoma（CheckMate 040)：An open-label，non-comparative，phase 1/2 dose escalation and expansion trial ［J］.The Lancet，2017,389(10088):2492-2502.
［24］Al Attar L，Truong P.The effect of pembrolizumab in absence of programmed death 1 receptor ［J］.Cureus，2018,10(6):e2896.
［25］Zhu AX，Finn RS，Edeline J，et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib（keynote-224)：A non-randomised，open-label phase 2 trial ［J］.The Lancet Oncology，2018,19(7):940-952.
［26］Mo H，Huang J，Xu J，et al.Safety，anti-tumour activity，and pharmacokinetics of fixed-dose SHR-1210，an anti-PD-1 antibody in advanced solid tumours:A dose-escalation，phase 1 study ［J］.British Journal of Cancer，2018,119(5):538-545.
［27］Qin SK，Ren ZG，Meng ZQ，et al.A randomized multicentered phase 2 study to evaluate SHR-1210（PD-1 antibody) in subjects with advanced hepatocellular carcinoma（HCC) who failed or were intolerant to prior systemic treatment ［J］.Ann Oncol，2018,29(suppl_8):viii719-viii720.
［28］WANG F,QIN SK,FANG WJ，et al.The clinicopathologic report of anti-PD-1 monoclonal antibody SHR-1210 in the treatment of cutaneous capillary hyperplasia induced by primary liver cancer ［J］.Chin Clin Oncol,2017,22(12):1066-1072.［王锋,秦叔逵,方维佳,等.抗PD-1单抗SHR-1210治疗原发性肝癌引发皮肤毛细血管增生症的临床病理报告［J］.临床肿瘤学杂志,2017,22(12):1066-1072.］
［29］Yu WC，Zhang KZ，Chen SG，et al.Efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma：A prospective observation study ［J］.Medicine，2018,97(3):e9704.
［30］Yasuda S，Sho M，Yamato I，et al.Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2（VEGFR2) induces synergistic anti-tumour effect in vivo ［J］.Clinical and Experimental Immunology，2013,172(3):500-506.
［31］Xu J，Zhang Y，Jia R，et al.Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma，gastric，or esophagogastric junction cancer：An open-label，dose escalation and expansion study ［J］.Clinical Cancer Research,2019,25(2):515-523.